LONDON --(BUSINESS WIRE)--Sep. 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m.   London time ( 8 a.m. Eastern Daylight Time ).

LONDON --(BUSINESS WIRE)--Sep. 1, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present at the Baird 2020 Global Healthcare Conference on Thursday, September 10 at 9:05 a.m.

LONDON --(BUSINESS WIRE)--Aug. 12, 2020-- LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve

LONDON --(BUSINESS WIRE)--Jul. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020 . For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million , a decrease

The next-generation sutureless surgical technology is based on a clinically proven platform and designed for valve durability LONDON --(BUSINESS WIRE)--Jul. 16, 2020-- LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval ®

LONDON --(BUSINESS WIRE)--Jul. 7, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials 1 , which details the design for “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem

LONDON --(BUSINESS WIRE)--Jun. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m.   London time ( 7 a.m. Eastern Daylight Time ).

LONDON --(BUSINESS WIRE)--Jun. 12, 2020-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S. subsidiary, LivaNova USA, Inc.

LONDON --(BUSINESS WIRE)--Jun. 11, 2020-- LivaNova PLC (NASDAQ:LIVN) (" LivaNova ") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S. subsidiary, LivaNova USA, Inc.

LONDON --(BUSINESS WIRE)--Jun. 11, 2020-- LivaNova PLC (NASDAQ:LIVN) (“The Company” or “LivaNova”) today announced its entry into a five-year $450 million senior secured credit facility (the “Credit Facility”) through its wholly owned U.S. subsidiary, LivaNova USA, Inc.

LONDON --(BUSINESS WIRE)--Jun. 1, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern Time .

PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LONDON --(BUSINESS WIRE)--May 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus

LONDON --(BUSINESS WIRE)--May 20, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders 1 that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy ® ) to

LONDON --(BUSINESS WIRE)--May 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval ® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at the 100 th Annual Meeting of the

LONDON --(BUSINESS WIRE)--May 11, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time .

LONDON --(BUSINESS WIRE)--Apr. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020 . For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million , a decrease

Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON --(BUSINESS WIRE)--Apr. 27, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned

Various products can now be used to treat patients experiencing acute respiratory or cardiopulmonary failure LONDON --(BUSINESS WIRE)--Apr. 22, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products

LONDON --(BUSINESS WIRE)--Mar. 30, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time ).

LONDON --(BUSINESS WIRE)--Mar. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of

Two UK patients receive innovative VNS Therapy implantable device through new pathway LONDON --(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System, Symmetry™, earned CE

RECOVER sub-study will leverage Verily research tools to provide quantitative assessment measures of depressive episodes LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with

LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019 . For the fourth quarter of 2019, worldwide sales were $287.6 million , a decrease of 3.2

LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler ® devices.

LONDON --(BUSINESS WIRE)--Feb. 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for

LONDON --(BUSINESS WIRE)--Jan. 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26, 2020 at 1 p.m. London time ( 8 a.m. Eastern Standard Time ).